Timing of Pessary Care

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02371083

Recruitment Status : Completed

First Posted : February 25, 2015

Last Update Posted : August 28, 2019

Sponsor:

Information provided by (Responsible Party):

Katie Propst, MD, Hartford Hospital

Study Description

Brief Summary:

This is a prospective trial to investigate optimal timing of care for vaginal pessaries. A vaginal pessary is a silicone device that is placed in the vagina to support the pelvic organs of a woman who has pelvic organ prolapse. Some women are willing and able to remove their own pessary on a regular basis. In women who are either unwilling or unable to remove their own pessary, complete pessary care is provided in the urogynecology office. Complete pessary care involves regular removal and cleaning of the pessary with a vaginal examination. In our practice, the investigators typically remove vaginal pessaries and examine the vagina every 3 months in patients for whom the investigators provide complete pessary care. Interval of pessary removal varies widely between practitioners. In the literature, removal intervals vary from weekly to yearly. In this study, the investigators will randomize participants to pessary care with removal every 12 weeks or every 24 weeks.

Condition or disease	Intervention/treatment	Phase
Pelvic Organ Prolapse	Other: Extended timing of pessary care	Not Applicable

Show detailed description

Detailed Description:

This is a prospective, randomized, non-blinded trial of office-based pessary care. The primary outcome of this study is vaginal epithelial abnormalities, including granulation tissue and ulceration. Secondary outcomes include participant satisfaction, degree of bother due to vaginal discharge, number of unscheduled visits and progression of pelvic organ prolapse quantification score (POPQS).

At baseline (visit 1; see "Visit Schedule", below), women who have consented to participate will be randomized 1:1 to one of two groups:

routine group: pessary care with removal and cleaning every 12 ± 2 weeks, or
extended group: pessary care with removal and cleaning every 24 ± 2 weeks.

Randomization will be performed using a randomization scheme available through Excel. Each consecutive/sequential participant will be assigned to whichever group corresponds to that sequential study entry number.

For both groups, the pessary will be removed and cleaned and a vaginal examination will be performed at every visit regardless of complaints. The only difference will be frequency of visits. All pelvic examinations will be performed by the same individual.

The study will be conducted for approximately one year, with additional time for analysis and preparation of abstract(s) and manuscript(s). Subjects' participation will consist of five visits in the routine group, three visits in the extended group. Consent to study participation will be obtained at the first visit. Visit schedule is shown below:

Visit Schedule Routine Group Visit #1, initial visit (week 0), procedures: Consent to participate, Collect Demographics, Pelvic examination /pessary removal Consent to participate Visit #2, interim visit (week 12 ± 2), procedures: Interview, Pelvic examination /pessary removal Visit #3, interim visit (week 24 ± 2), procedures: Interview, Pelvic examination /pessary removal Visit #4, interim visit (week 36 ± 2), procedures: Interview, Pelvic examination /pessary removal Visit #5, final visit (week 48 ± 2), procedures: Interview, Pelvic examination /pessary removal

Extended Group Visit #1, initial visit (week 0), procedures: Consent to participate, Collect Demographics, Pelvic examination /pessary removal Consent to participate Visit #2, interim visit (week 24 ± 2), procedures: Interview, Pelvic examination /pessary removal Visit #3, final visit (week 48 ± 2), procedures: Interview, Pelvic examination /pessary removal

Participants who are approaching the upper bound of their visit window will be reminded of the need for a visit. Those who still present outside of the window for the interim visit will be scheduled their next appointment as it would have been scheduled if they had presented for the visit at the correct time. Any such cases will be noted in the analysis and a protocol deviation form will be completed and sent to IRB. Any participant who misses three visits within the scheduled window will be withdrawn from the study.

Consent to study participation will occur at visit #1, a vaginal examination will be performed to document a pelvic organ prolapse quantification score8 (POPQS) and to exclude the presence of vaginal epithelial abnormalities (granulation tissue, erosion), or fistula and to note the presence of vaginal adhesions.

Additional data will be collected at the initial visit: age, body mass index (BMI), smoking status, history of diabetes mellitus, history of surgery for incontinence or pelvic organ prolapse, history of hysterectomy, indication for pessary use, pessary size and type, duration of pessary use of the current pessary and in total if the participant has used other pessaries in the past, whether the participant has an intimate partner, use of aspirin (ASA) and dose, use of anticoagulation therapy, parity, bother from vaginal discharge, presence of vaginal bleeding, and history of vaginal epithelial abnormalities. The investigators also will document if the participant is using hormone replacement (HRT). If the participant is using HRT, the investigators will document medication, dose, route and frequency.

Participants will be followed for 48 ± 2 weeks. At interim visits, data will be assessed for updates:

Has the participant started new medications (ASA, anticoagulation, HRT)? Is the subject bothered by vaginal discharge? Is vaginal bleeding present?

At interim visits, when a pessary is removed, a vaginal examination will be performed to evaluate for the presence of vaginal epithelial abnormalities and vaginal adhesions. When abnormalities are noted, they will be described in appearance, location, number, and size. Additionally, abnormalities will be staged using the following system:

Stage Description

Epithelial erythemya without epithelial breaks or presence of granulation tissue ≤1cm in size.
Epithelial break or erosion ≤ 0.5 cm in diameter or presence of granulation tissue >1cm in size.
Epithelial break or erosion 1-2cm in diameter.
Epithelial break or erosion > 2 cm in diameter.

If there is more than one epithelial abnormality noted, each will each be assigned a stage. The highest stage abnormality will determine the overall stage of the epithelial abnormality.

If there is a change in pessary type or size, this will be documented. If the pessary is changed to a type other than ring or gellhorn, the participant will continue in the study as scheduled. If a pessary is removed and left out of the vagina, this will be documented. At the final visit, all participants will undergo a pelvic examination with pessary removal.

Data will be collected on forms designed according to study group (routine/extended) and visit number. In the case that a participant has a pessary complaint and requires evaluation in the office outside of the scheduled visits according to their group allocation, an unscheduled visit form will be used to collect data at this visit. At an unscheduled visit, the same data will be collected as is collected at a scheduled follow-up visit. Additionally, the participant's complaint/visit reason will be described.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	130 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Timing of Pessary Care
Actual Study Start Date :	January 2015
Actual Primary Completion Date :	May 2018
Actual Study Completion Date :	June 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pelvic Support Problems

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
No Intervention: Routine Subjects will continue with regular pessary care every 12 weeks.
Experimental: Extended Subjects will have extended time between pessary care visits which will occur every 24 weeks.	Other: Extended timing of pessary care

Outcome Measures

Primary Outcome Measures :

vaginal epithelial abnormalities [ Time Frame: Routine group: change from baseline in vaginal epithelial abnormalities at 12 weeks, 24 weeks, 36 weeks, 48 weeks. Extended group: change from baseline in vaginal epithelial abnormalities at 24 weeks, 48 weeks ]
this will be evaluated by vaginal examination at each study visit

Secondary Outcome Measures :

Patient satisfaction [ Time Frame: final study visit (48 weeks) ]
this will be evaluated at the final visit by asking patients if they preferred more or less frequent pessary visits
Degree of bother due to vaginal discharge [ Time Frame: Routine group: change from baseline in degree of bother due to vaginal discharge at 12 weeks, 24 weeks, 36 weeks, 48 weeks. Extended group: change from baseline in degree of bother due to vaginal discharge at 24 weeks, 48 weeks ]
this will be assessed by asking participants how bothersome is vaginal discharge on a 5-point likert scale
Progression of Pelvic Organ Prolapse Quantification Score [ Time Frame: Change from baseline in pelvic organ prolapse quantification score at final study visit (48 weeks) ]
this will be evaluated by measuring a pelvic organ prolapse quantification score on physical examination

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

female sex
age greater than 17 years
able and willing to participate
patients who are currently wearing a ring, gellhorn, or incontinence dish pessary to treat pelvic organ prolapse and/or incontinence

Exclusion Criteria:

male sex
age less than 18 years
unable/unwilling to participate
patients who do not wear a pessary
patients wearing a pessary that is not a ring or a gellhorn
presence of vaginal granulation tissue
erosions, or fistula, patients who perform pessary self-care

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02371083

Locations

Layout table for location information

United States, Connecticut
Hartford Hospital, Urogynecology Division
Hartford, Connecticut, United States, 06106

Sponsors and Collaborators

Hartford Hospital

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Bugge C, Adams EJ, Gopinath D, Stewart F, Dembinsky M, Sobiesuo P, Kearney R. Pessaries (mechanical devices) for managing pelvic organ prolapse in women. Cochrane Database Syst Rev. 2020 Nov 18;11:CD004010. doi: 10.1002/14651858.CD004010.pub4.

Propst K, Mellen C, O'Sullivan DM, Tulikangas PK. Timing of Office-Based Pessary Care: A Randomized Controlled Trial. Obstet Gynecol. 2020 Jan;135(1):100-105. doi: 10.1097/AOG.0000000000003580.

Layout table for additonal information

Responsible Party:	Katie Propst, MD, Fellow, Hartford Hospital
ClinicalTrials.gov Identifier:	NCT02371083
Other Study ID Numbers:	HHC-2014-0112
First Posted:	February 25, 2015 Key Record Dates
Last Update Posted:	August 28, 2019
Last Verified:	August 2019

Keywords provided by Katie Propst, MD, Hartford Hospital:


Pelvic organ prolapse managed by vaginal pessary

Additional relevant MeSH terms:

Layout table for MeSH terms

Prolapse Pelvic Organ Prolapse Pathological Conditions, Anatomical

To Top